<DOC>
	<DOC>NCT01476813</DOC>
	<brief_summary>dose-finding study to assess the optimal dose of glycopyrrolate daily dose on top of BDP/FF in COPD patients.</brief_summary>
	<brief_title>Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate</brief_title>
	<detailed_description>A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED, 4-WAY CROSS-OVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A FREE COMBINATION OF 3 DOSES OF GLYCOPYRROLATE WITH FIXED COMBINATION BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL (FOSTERÂ®) IN A METERED DOSE INHALER FOR THE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>COPD over 40 years of age (30 to 60% postbronchodilator FEV1 predictive value) Patients under Double Patients under triple therapy (for 1 Mo prior Screening) Pregnant or lactating women Patients experiencing a COPD exacerbation requiring use of systemic steroids and/or antibiotics, hospitalization concommitant diseases impacting feasibility or safety</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>